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Summary We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6
years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff,
Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in
patients who received hormone therapy, in whom pS2 status was also predictive of the response to
therapy.
Proliferation of human breast cancer can be oestradiol
dependent. In such cases hormonal therapy provides an
objective benefit. The failure of 30-40% of patients with
oestradiol receptor (ER)-rich tumours to respond to endo-
crine therapy was ascribed to either tumour heterogeneity or
absence of progesterone receptor (PR) (McGuire et al., 1978;
Jensen et al., 1982). Determination of PR content improves
the diagnosis of hormone dependence (Horwitz et al., 1975),
but about 20% of ER-positive, PR-positive tumours do not
respond to hormone therapy. There is thus a need for other
markers of hormone responsiveness.
The pS2 gene has been cloned in the breast cancer cell line
MCF7 cDNA library (Masiakovski et al., 1982), and its
expression is oestradiol regulated at the transcriptional level
through the ER pathway (Berry et al., 1989). Both pS2
mRNA and protein have been observed in human breast
tumours (Rio et al., 1987; Henry et al., 1989, 1991; Foekens
et al., 1990, 1993; Guerin et al., 1990; Wysocki et al., 1990;
Goussard et al., 1991; Schwartz et al., 1991; Klijn et al.,
1992; Koerner et al., 1992; Predine et al., 1992; Thor et al.,
1992, Thomson et al., 1993). In all studies, a positive correla-
tion was observed between pS2 expression and oestrogen
receptor status. Moreover, a retrospective study showed that
pS2 expression was associated with a good prognosis
(Foekens et al., 1990). More recently, the value of pS2 in
predicting the response to hormone therapy in primary
(Predine et al., 1992) and advanced breast cancer (Henry et
al., 1989, 1991; Schwartz et al., 1991; Klijn et al., 1992) has
been reported.
We reviewed 319 primary breast tumours for cytosolic pS2
content using the ELSA-pS2 kit (CIS-Bio-industries, Gif-sur-
Yvette, France). Both prognostic value (319 patients) and
predictive value for the response to adjuvant hormone
therapy (84 of the 319 patients) were evaluated.
Materials and methods
Patients
The 319 patients in this study (mean age 55 years; range
30-86) were treated at the Centre Rene Huguenin (CRH)
between 1980 and 1985. The median follow-up was 6 years
(maximum 10 years). Patients were selected from a regularly
updated computerised database and the corresponding
tumour specimens were taken from a liquid nitrogen tumour
bank according to the following criteria: primary, without
metastasis, operable unilateral breast cancer, ER and PR
assayed on the primary tumour, no other primary cancer, full
follow-up at the CRH, complete information on the patients
(Table I).
All patients were staged at the time of diagnosis according
to the UICC TNM classification (1978). The histoprognostic
grade of the tumour was determined according to the method
of Scarff, Bloom and Richardson (SBR) (Bloom & Richard-
son, 1957; Scarff & Torloni, 1968). ER and PR were assayed
at the time of surgery by means of the dextran-coated char-
coal method. Quality control was assured by frequent testing
with both internal controls and EORTC (1980) standards.
All patients underwent either total or partial axillary
dissection; all nodes (mean number of nodes examined 14)
were then embedded and serially sectioned. A total of 187
patients (58%) underwent a modified radical mastectomy and
132 (42%) underwent partial mastectomy with axillary lymph
node clearance. Forty-two patients who underwent partial
mastectomy also received peroperative brachytherapy.
Patients (n = 117) regarded as high risk (more than three
involved axillary lymph nodes or at least one involved axil-
lary lymph node, grade III tumour or age below 35 years)
received post-operative-chemotherapy [mainly FAC
(adriamycin, 5-fluorouracil, cyclophosphamide) or CMF
(cyclophosphamide, methotrexate, 5-flurouracil) n = 29], hor-
mone therapy (premenopausal women, castration plus tamo-
xifen 20 mg day-' for 3 years; post-menopausal women,
tamoxifen 20 mg day-' for 3 years, n = 44) or both (n = 40).
Peroperative thiotepa was given to 297 patients. All the
patients underwent clinical, radiological and laboratory
examinations every 3 months for the first 2 years, then
yearly.
At the time of analysis, 91 patients had relapsed (local
recurrence and/or distant metastasis) and 68 patients had
died of cancer.
Cytosolic samples
For this study, samples were homogenised in 10 mM Tris-HCl
buffer, pH 7.4, containing 1.5 mM EDTA, 0.5 mM dithio-
threitol and 10% glycerol. Cytosols were aliquoted and
stored in liquid nitrogen until use (within 1 month). Cytosolic
pS2 was assayed with a commercial immunoradiometric
method (ELSA-pS2 kit, CIS, Bio-Industries, Gif-sur-Yvette,
France), validated elsewhere (Goussard et al., 1991). Protein
was assayed by means of the Bradford technique (Biorad
Laboratories, Munich, Germany). Laboratory results were
interpreted at the CRH in blinded fashion.
Statistical methods
Differences in the distribution of characteristics between
patient subgroups were analysed using the chi-squared test.
Continuous variables were transformed into binary variables.
With the exception of hormone receptors, the cut-off values
were determined using the distribution-dependent Fisher
(1958) method, without reference to outcome. Patients were
arranged in order of increasing pS2 values. A frequency
distribution of the values was plotted in ten subgroups. These
subgroups were combined to form two large groups, to give a
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Table I Distribution of clinical, histological and biological variables according to pS2
status
pS2 (1.9 pS2>1.9
(ngmg-' protein) (ngmg-' protein) P-value?
Age
<54 years 164 37 (22.5%) 127 (77.4%) 0.01
> 54 years 155 59 (38.0%) 96 (61.8%)
Menopausal status
Premenopausal 145 31 (21.3%) 114 (78.6%) 0.008
Post-menopausal 174 65 (37.3%) 109 (62.6%)
Clinical tumour size
<34mm 160 47 (29.3%) 113 (70.5%) 0.3
>34mm 159 49 (30.8%) 110 (69.1%)
Macroscopic
tumour size (pT)
<29mm 225 69 (30.6%) 156 (69.3%) 0.7
29mm 94 27 (28.7%) 67 (71.2%)
SBR gradeb
I 30 7 (23.3%) 23 (76.6%)
II 202 43 (21.2%) 159 (78.6%) <0.001
III 87 46 (52.8%) 41 (47.0%)
Axillary node status
Negative 151 43 (28.5%) 108 (71.5%) 0.5
Positive 168 53 (31.5%) 115 (68.3%)
Oestrogen receptor level
<10 fmol mg' protein 96 44 (45.8%) 52 (54.1%) <0.001
> 10fmol mg-' protein 223 52 (23.3%) 171 (76.6%)
Progesterone receptor level
<10 fmol mg-' protein 138 52 (37.6%) 86 (62.2%) 0.01
> 10fmol mg-' protein 181 44 (24.3%) 137 (75.6%)
UICC stage
I 55 14 (25.4%) 41 (74.4%)
II 224 71 (31.6%) 153 (68.2%) 0.7
III 40 11 (27.5%) 29 (72.5%)
Total 96 223
'P-values of the x2 test. bThe histoprognostic grade of the tumour was determined
according to the method of Scarff, Bloom and Richardson.
small variance in the estimate of the mean for all patients.
We calculated the sum of the squares within groups for each
pair of adjacent subgroups, and the combination of sub-
groups into two large groups that gave the minimum sum of
squares was selected. The two groups were analysed by x2.
Kaplan-Meier (1958) disease-free (DFS) and overall survival
(OS) curves were analysed by the log-rank test. The most
significant prognostic factors were identified by a forward
selection procedure based on the Cox proportional hazards
model (Cox, 1972). Candidate variables in the Cox model are
listed in Table I. DFS was defined as the time to the first
local relapse or distant metastasis, and OS as the time to
death from cancer.
Results
pS2 distribution
The pS2 values ranged from 0 to 699.7 ng per mg of protein
(mean 30.57 + 76.67; median 6.4). The cut-off was set at
1.9 ngmg-' protein according to the Fisher method (without
reference to outcome). With this cut-off, 30.09% (96 out of
319) of the tumours were pS2 negative. The distribution of
classical parameters according to pS2 status is shown in
Table I. Higher pS2 values were found in young (<54 years)
and premenopausal patients. pS2 status correlated positively
with ER and PR and negatively with SBR grade; pS2 did not
correlate with clinical and macroscopic tumour size, UICC
stage or nodal status.
Univariate prognostic analysis
Using univariate analysis (log-rank test), pS2 as a
dichotomous variable (1.9 ng mg-' protein) was negatively
related to DFS (P = 0.057) and OS (P = 0.01) (data not
shown).
Multivariate prognostic analysis
The multivariate Cox analysis was carried out using the
following parameters: age, menopausal status, clinical and
histological tumour size, SBR grade, nodal status, ER, PR
and UICC stage (Table I). In the overall population, pS2 was
the first parameter excluded for DFS, while pS2 was the
second independent variable for OS after nodal status (Table
Ila). Overall survival curves defined by the two independent
variables (nodal involvement and pS2 status) are shown in
Figure 1. The longest survival time was observed among
patients without node involvement and those whose tumours
expressed pS2 protein. In contrast, patients with node
involvement and pS2-negative primary tumours had an eight-
fold higher risk of death.
In patients not receiving hormone therapy (Table Ilb),
nodal status was the only significant variable for DFS and
OS. In patients receiving hormone therapy (Table lIc), three
parameters were identified as independent variables for OS:
nodal status, pS2 and age. Nodal status was the only selected
variable for DFS (pS2 was the first excluded variable).
Discussion
Mean (30 ng mg-' protein) and median (6.4 ngmg-' protein)
pS2 values correlated well with those (24 and 6 ng mg-')
reported by Goussard et al. (1991) and those (29 and
4.9 ng mg 1) reported by Foekens et al. (1993), using the
same immunoradiometric assay. Agreement between prospec-
tive (Goussard et al., 1991) and retrospective studies396 F. SPYRATOS et al.
Table II Multivariate Cox analyses of disease-free survival and overall survival
(a) Overall population (319 patients)
Disease-free survival Overall survival
Regression Maximised log Regression Maximised log
Variablea coefficient likelihood P-value coefficient likelihood P-value
Nodal status 0.53 - 496.06 0.004 1.22 - 349.59 < 10-4
pS2 - - - 0.68 - 346.13 0.008
Tumour size 0.51 - 493.29 0.018 - - -
(b) No hormone therapy (235 patients)
Disease-free survival Overall survival
Regression Maximised log Regression Maximised log
Variable coefficient likelihood P-value coefficient likelihood P-value
Nodal status 0.78 -482.19 0.001 1.18 -335.28 0.0004
(c) Hormone therapy (84 patients)
Disease-free survival Overall survival
Regression Maximised log Regression Maximised log
Variable coefficient likelihood P-value coefficient likelihood P-value
Nodal status 1.68 -81.19 0.0014 2.17 -85.08 0.0004
pS2 - - - 1.35 - 80.73 0.003
Age -1.13 -77.32 0.009
aCandidate variables in the Cox model are those listed in Table I.
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Figure 1 Overall survival curves of the 319 primary breast
cancer patients according to the four risk groups defined by the
combination of the two significant variables of the Cox model,
nodal and pS2 status (P-value of the log-rank test).
(Foekens et al., 1993) and the present study indicates good
preservation of our samples. Similarly, our cut-off value
(1.9 ng mg' protein) is in keeping with the value in latest
study by Foekens et al. (1993) (2 ng mg-' protein), in spite of
the different statistical approach used to calculate the cut-off.
The percentages of pS2-positive tumours were also similar
(70% vs 61%).
As reported in all previous studies, there was a strong
positive correlation between ER gene and pS2 gene expres-
sion. Moreover, we confirmed a correlation between meno-
pausal status (and age) and pS2 found by Foekens et al.
(1990) and Predine et al. (1992). The general tendency for
pS2 to be more frequently positive in well-differentiated
tumours (Predine et al., 1992; Thor et al., 1992; Foekens et
al., 1993) was also confirmed here. No relation was found
between pS2 and tumour size or nodal status, as previously
reported (Henry et al., 1989; Foekens et al., 1990, 1993;
Schwartz et al., 1991; Predine et al., 1992; Thor et al., 1992).
In a univariate analysis, pS2 positivity was significantly
associated with prolonged disease-free and overall survival,
again as already reported (Foekens et al., 1990; Predine et
al., 1992; Thor et al., 1992).
Using Cox multivariate analysis, nodal status was the most
important predictive parameter for DFS and OS in these
patients with breast cancer. Moreover, in the hormone-
treated population, this parameter was the only one that
significantly predicted DFS. Although pS2 appears to be
poorly predictive of DFS, it was the second independent
predictor for the OS, after nodal status. These results for pS2
imply that pS2 protein is not related to the ability of breast
tumours to recur and/or form metastases, but rather to the
aggressiveness of recurrences and metastases, perhaps
through their stage of differentiation, as in the primary
tumours. Interestingly, the pS2 value was prognostic both in
the overall population and in the hormone-treated patient
population, but not in the patients not treated with hor-
mones. Hence, the significance of the pS2 value is related to
hormone treatment: patients with tumours containing pS2
respond and survive longer. In other words, the improved
survival in the pS2-positive population reflects the response
of pS2-containing tumours to endocrine therapy. Such a
correlation between pS2 gene expression and a positive re-
sponse to hormone therapy has already been observed in the
treatment of both primary (Predine et al., 1992) and
advanced (Henry et al., 1989, 1991; Schwartz et al., 1991;
Klijn et al., 1992) breast carcinomas. Moreover, pS2 status
appears to be more informative than ER and/or PR for
selecting patients for hormone treatment.
In conclusion, biological prognostic factors should be
viewed not only as parameters that might influence the rate
of relapse and death, but also as factors with potential
influence on the response to treatment. Overall, the present
study confirms that pS2 should be considered as predictive of
the response to hormone therapy. The favourable outcome of
patients whose tumours express pS2 protein appears to be
due both to the favourable effects of endocrine therapy and,
to some extent, to an inherently favourable tumour
biology.
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